LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

14 -0.07

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.99

Max

14.26

Belangrijke statistieken
By Trading Economics
Inkomsten	-2.2M -12M
Werknemers	37
EBITDA	-2.1M -12M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+128.41% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-176M 1.2B
Vorige openingsprijs	14.07
Vorige sluitingsprijs	14

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

3.165 / 3.5827 Steun & Weerstand

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 mrt 2026, 17:33 UTC

Belangrijke Nieuwsgebeurtenissen

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 mrt 2026, 17:00 UTC

Belangrijke Nieuwsgebeurtenissen

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 mrt 2026, 16:03 UTC

Belangrijke Nieuwsgebeurtenissen

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

29 mrt 2026, 23:47 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Falls Amid Rising Inflation Fears -- Market Talk

29 mrt 2026, 23:46 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

29 mrt 2026, 23:35 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

29 mrt 2026, 23:23 UTC

Marktinformatie

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

29 mrt 2026, 22:34 UTC

Marktinformatie

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

29 mrt 2026, 22:09 UTC

Marktinformatie

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

29 mrt 2026, 21:06 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

29 mrt 2026, 21:03 UTC

Marktinformatie

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

29 mrt 2026, 21:01 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

29 mrt 2026, 09:30 UTC

Acquisities, Fusies, Overnames

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

28 mrt 2026, 08:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 19:16 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 mrt 2026, 19:07 UTC

Marktinformatie

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 mrt 2026, 19:04 UTC

Marktinformatie

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 mrt 2026, 19:03 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 19:02 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 mrt 2026, 18:12 UTC

Marktinformatie

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 mrt 2026, 17:36 UTC

Belangrijke Nieuwsgebeurtenissen

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 mrt 2026, 17:34 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 mrt 2026, 17:29 UTC

Marktinformatie

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 mrt 2026, 16:38 UTC

Marktinformatie

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 mrt 2026, 16:32 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 mrt 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 15:43 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 mrt 2026, 15:25 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 15:25 UTC

Marktinformatie

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

128.41% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 32 USD 128.41%

Hoogste 42 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.165 / 3.5827Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.